Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring

Haematologica

Volumn 100, Issue 3, 2015, Pages e93-e96

  Oelschlaegel, Uta ^a   Westers, Theresia M ^b   Mohr, Brigitte ^a   Kramer, Michael ^a   Parmentier, Stefani ^a   Sockel, Katja ^a   Thiede, Christian ^a   Bornhäuser, Martin ^a   Ehninger, Gerhard ^a   Van De Loosdrecht, Arjan A ^b   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CD71 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LENALIDOMIDE; PROTEIN P53; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; THALIDOMIDE;

COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FLOW CYTOMETRY; GENE DELETION; GENETIC ASSOCIATION; GRANULOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; BONE MARROW; BONE MARROW CELL; CHROMOSOME 5; CHROMOSOME DELETION; DRUG EFFECTS; DRUG MONITORING; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

ANTIGENS, CD; BONE MARROW; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COHORT STUDIES; DRUG MONITORING; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; LYMPHOCYTES; MALE; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; THALIDOMIDE;

EID: 84924674398     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115725     Document Type: Letter

References (15)

1. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/ neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France, PA: IARC; 2008. p.88-93.
2. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1):113-119.
3. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730-1741.
4. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403.
5. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-1074.
6. van de Loosdrecht AA, Alhan C, Béné MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94(8):1124-1134.
7. Chung JW, Park CJ, Cha CH, et al. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome. Ann Clin Lab Sci. 2012;42(3):271-280.
8. Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002;100(7):2349-2356.
9. Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected Myelodysplastic Syndrome. Cancer. 2010; 116(19):4549-4563.
10. Xu F, Wu L, He Q, et al. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndrome. Intern Med J. 2012;42(4):401-411.
11. Hasserjian RP, Le Beau MM, List AF, Bennett JM, Thiele J. Myelodysplastic syndrome with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France, PA: IARC; 2008. p.102.
12. Tehranchi R, Woll PS, Anderson K, et al. Persistant malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025-1037.
13. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
14. Platzbecker U, Braulke F, Kündgen A, et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia. 2013;27(6):1403-1407.
15. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51 (12):1086-1092.